Warfarin-amiodarone drug-drug interactions: Determination of [I] u/K I,u for amiodarone and its plasma metabolites

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 4, 2012, Pages 709-717

  McDonald, M G ^a   Au, N T ^a   Wittkowsky, A K ^b   Rettie, A E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; DRUG METABOLITE; N,N DIDESETHYLAMIODARONE; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; HUMAN CELL; HYDROXYLATION; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; AMIODARONE; CHROMATOGRAPHY, LIQUID; COHORT STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; WARFARIN; YOUNG ADULT;

EID: 84858797097     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.283     Document Type: Article

References (43)

1. Vastesaeger, E. [Fibrin and atherosclerosis]. Acta Cardiol. 22, 581-586 (1967).
2. Julian, D.G. et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 349, 667-674 (1997). (Pubitemid 27107744)
3. Mason, J.W. Amiodarone. N. Engl. J. Med. 316, 455-466 (1987).
4. Heger, J.J., Prystowsky, E.N. & Zipes, D.P. Relationships between amiodarone dosage, drug concentrations, and adverse side effects. Am. Heart J. 106, 931-935 (1983). (Pubitemid 13010828)
5. Marchlinski, F.E., Gansler, T.S., Waxman, H.L. & Josephson, M.E. Amiodarone pulmonary toxicity. Ann. Intern. Med. 97, 839-845 (1982). (Pubitemid 13240564)
6. Rigas, B. et al. Amiodarone hepatotoxicity. A clinicopathologic study of five patients. Ann. Intern. Med. 104, 348-351 (1986). (Pubitemid 16163612)
7. Dickstein, G., Amikam, S., Riss, E. & Barzilai, D. Thyrotoxicosis induced by amiodarone, a new efficient antiarrhythmic drug with high iodine content. Am. J. Med. Sci. 288, 14-17 (1984). (Pubitemid 14053220)
8. Trujillo, T.C. & Nolan, P.E. Antiarrhythmic agents: drug interactions of clinical significance. Drug Saf. 23, 509-532 (2000). (Pubitemid 32001513)
9. Funck-Brentano, C. et al. Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. Clin. Pharmacol. Ther. 55, 256-269 (1994).
10. Chitwood, K.K., Abdul-Haqq, A.J. & Heim-Duthoy, K.L. Cyclosporineamiodarone interaction. Ann. Pharmacother. 27, 569-571 (1993).
11. Nicolau, D.P., Uber, W.E., Crumbley, A.J. 3rd & Strange, C. Amiodaronecyclosporine interaction in a heart transplant patient. J. Heart Lung Transplant. 11, 564-568 (1992).
12. Funck-Brentano, C., Jacqz-Aigrain, E., Leenhardt, A., Roux, A., Poirier, J.M. & Jaillon, P. Influence of amiodarone on genetically determined drug metabolism in humans. Clin. Pharmacol. Ther. 50, 259-266 (1991).
13. Thi, L., Shaw, D. & Bird, J. Warfarin potentiation: a review of the "FAB-4" significant drug interactions. Consult. Pharm. 24, 227-230 (2009).
14. Lip, G.Y. & Lim, H.S. Atrial fibrillation and stroke prevention. Lancet Neurol. 6, 981-993 (2007). (Pubitemid 47566414)
15. Kerin, N.Z., Blevins, R.D., Goldman, L., Faitel, K. & Rubenfire, M. The incidence, magnitude, and time course of the amiodarone-warfarin interaction. Arch. Intern. Med. 148, 1779-1781 (1988).
16. Sanoski, C.A. & Bauman, J.L. Clinical observations with the amiodarone/warfarin interaction: dosing relationships with long-term therapy. Chest 121, 19-23 (2002). (Pubitemid 34114223)
17. O'Reilly, R.A., Trager, W.F., Rettie, A.E. & Goulart, D.A. Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. Clin. Pharmacol. Ther. 42, 290-294 (1987). (Pubitemid 17155734)
18. Heimark, L.D. et al. The mechanism of the interaction between amiodarone and warfarin in humans. Clin. Pharmacol. Ther. 51, 398-407 (1992).
19. Kumar, V., Locuson, C.W., Sham, Y.Y. & Tracy, T.S. Amiodarone analogdependent effects on CYP2C9-mediated metabolism and kinetic profiles. Drug Metab. Dispos. 34, 1688-1696 (2006). (Pubitemid 44427471)
20. Ohyama, K., Nakajima, M., Suzuki, M., Shimada, N., Yamazaki, H. & Yokoi, T. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br. J. Clin. Pharmacol. 49, 244-253 (2000). (Pubitemid 30150986)
21. Rettie, A.E. et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol. 5, 54-59 (1992).
22. Marchiset, D., Bruno, R., Djiane, P., Cano, J.P., Benichou, M. & Serradimigni, A. Amiodarone and desethylamiodarone elimination kinetics following withdrawal of long-term amiodarone maintenance therapy. Biopharm. Drug Dispos. 6, 209-215 (1985). (Pubitemid 15092221)
23. Naganuma, M., Shiga, T., Nishikata, K., Tsuchiya, T., Kasanuki, H. & Fujii, E. Role of desethylamiodarone in the anticoagulant effect of concurrent amiodarone and warfarin therapy. J. Cardiovasc. Pharmacol. Ther. 6, 363-367 (2001). (Pubitemid 34141821)
24. Ha, H.R., Bigler, L., Wendt, B., Maggiorini, M. & Follath, F. Identification and quantitation of novel metabolites of amiodarone in plasma of treated patients. Eur. J. Pharm. Sci. 24, 271-279 (2005). (Pubitemid 40283509)
25. Harris, L. & Roncucci, R.R. Amiodarone: Pharmacology, Pharmacokinetics, Toxicology, Clinical Effects (M?ecine et sciences internationales: Paris, France, 1986).
26. Locuson, C.W. 2nd, Wahlstrom, J.L., Rock, D.A., Rock, D.A. & Jones, J.P. A new class of CYP2C9 inhibitors: probing 2C9 specificity with high-affinity benzbromarone derivatives. Drug Metab. Dispos. 31, 967-971 (2003).
27. Lucas, A.N., Tanol, M., McIntosh, M.P. & Rajewski, R.A. Preparation and purification of desethylamiodarone hydrochloride. Synth. Commun. 36, 3371-3376 (2006). (Pubitemid 44764424)
28. Waldhauser, K.M. et al. Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives. J. Pharmacol. Exp. Ther. 319, 1413-1423 (2006).
29. Snead, A.N., Miyakawa, M., Tan, E.S. & Scanlan, T.S. Trace amine-associated receptor 1 (TAAR1) is activated by amiodarone metabolites. Bioorg. Med. Chem. Lett. 18, 5920-5922 (2008).
30. Wendt, B., Ha, H.R. & Hesse, M. Synthesis of two metabolites of the antiarrythmicum amiodarone. Helv. Chim. Acta 85, 2990-3001 (2002). (Pubitemid 35177814)
31. Deng, P., You, T.G., Chen, X.Y., Yuan, T., Huang, H.H. & Zhong, D.F. Identification of amiodarone metabolites in human bile by ultra performance liquid chromatography/quadrupole time-of-flight mass spectrometry. Drug Metab. ispos. 39, 1058-1069 (2011).
32. Lalloz, M.R., Byfield, P.G., Greenwood, R.M. & Himsworth, R.L. Binding of amiodarone by serum proteins and the effects of drugs, hormones and other interacting ligands. J. Pharm. Pharmacol. 36, 366-372 (1984). (Pubitemid 14104814)
33. US Food and Drug Administration. Guidance for industry drug interaction studies-study design, data analysis, and implications for dosing and labeling. Draft guidance. (Rockville, MD, 2006).
34. Yeung, C.K., Fujioka, Y., Hachad, H., Levy, R.H. & Isoherranen, N. Are circulating metabolites important in drug-drug interactions?: quantitative analysis of risk prediction and inhibitory potency. Clin. Pharmacol. Ther. 89, 105-113 (2011).
35. Blanchard, N., Richert, L., Coassolo, P. & Lav? T. Qualitative and quantitative assessment of drug-drug interaction potential in man, based on Ki, IC50 and inhibitor concentration. Curr. Drug Metab. 5, 147-156 (2004). (Pubitemid 38515244)
36. Ito, K. et al. Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS PharmSci 4, E25 (2002).
37. Obach, R.S. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab. Dispos. 25, 1359-1369 (1997). (Pubitemid 28010921)
38. Hanson, K.L., VandenBrink, B.M., Babu, K.N., Allen, K.E., Nelson, W.L. & Kunze, K.L. Sequential metabolism of secondary alkyl amines to metabolic-intermediate complexes: opposing roles for the secondary hydroxylamine and primary amine metabolites of desipramine, (s)-fluoxetine, and N-desmethyldiltiazem. Drug Metab. Dispos. 38, 963-972 (2010).
39. Mori, K., Hashimoto, H., Takatsu, H., Tsuda-Tsukimoto, M. & Kume, T. Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development. Xenobiotica. 39, 415-422 (2009).
40. European Medicines Agency. Guideline on the investigation of drug interactions (Canary Wharf, London, 2010).
41. Sadeque, A.J., Eddy, A.C., Meier, G.P. & Rettie, A.E. Stereoselective sulfoxidation by human flavin-containing monooxygenase. Evidence for catalytic diversity between hepatic, renal, and fetal forms. Drug Metab. Dispos. 20, 832-839 (1992).
42. Nakai, D., Kumamoto, K., Sakikawa, C., Kosaka, T. & Tokui, T. Evaluation of the protein binding ratio of drugs by a micro-scale ultracentrifugation method. J. Pharm. Sci. 93, 847-854 (2004). (Pubitemid 38420397)
43. Templeton, I.E. et al. Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clin. Pharmacol. Ther. 83, 77-85 (2008).